The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice

被引:2
|
作者
Xu, Kangwei [1 ]
Li, Jing [2 ]
Lu, Xu [1 ]
Ge, Xiaoqin [2 ]
Wang, Kaiqin [1 ]
Wang, Jiahao [2 ]
Qiao, Zhizhong [1 ]
Quan, Yaru [1 ]
Li, Changgui [1 ]
机构
[1] Natl Inst Food & Drug Control, NHC Key Lab Res Qual & Standardizat Biotech Prod, NMPA Key Lab Qual Res & Evaluat Biol Prod, 2 Tiantan Xili, Beijing 100050, Peoples R China
[2] Sinovac Life Sci Co Ltd, Daxing Biomed Ind Base Zhongguancun Sci Pk, 21 Tianfu St, Beijing 100050, Peoples R China
基金
北京市自然科学基金;
关键词
SARS-CoV-2; inactivated vaccines; Delta; immunogenicity; adjuvants;
D O I
10.3390/vaccines12010060
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The continuous evolution and mutation of SARS-CoV-2 have highlighted the need for more effective vaccines. In this study, CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines were prepared, and the immunogenicity of these vaccines in mice was evaluated. The Delta + MF59-like vaccine group produced the highest levels of S- and RBD-binding antibodies and live Delta virus neutralization levels after one shot of immunization, while mice in the Delta + Alum vaccine group had the highest levels of these antibodies after two doses, and the Delta + MF59-like and Delta + Alum vaccine groups produced high levels of cross-neutralization antibodies against prototype, Beta, and Gamma strain SARS-CoV-2 viruses. There was no significant decrease in neutralizing antibody levels in any vaccine group during the observation period. CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines excited different antibody subtypes compared with unadjuvanted vaccines; the Delta + CpG vaccine group had a higher proportion of IgG2b antibodies, indicating bias towards Th1 immunity. The proportions of IgG1 and IgG2b in the Delta + MF59-like vaccine group were similar to those of the unadjuvanted vaccine. However, the Delta + Alum vaccine group had a higher proportion of IgG1 antibodies, indicating bias towards Th2 immunity. Antigen-specific cytokine secretion CD4/8+ T cells were analyzed. In conclusion, the results of this study show differences in the immune efficacy of CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines in mice, which have significant implications for the selection strategy for vaccine adjuvants.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice
    Bai, Shuang
    Kang, Yanli
    Chen, Weixin
    Xie, Hui
    Zhang, Lichi
    Lv, Min
    Wang, Jian
    Wu, Jiang
    Zhao, Wei
    VIRAL IMMUNOLOGY, 2023, 36 (08) : 526 - 533
  • [2] The immunogenicity of Alum plus CpG adjuvant SARS-CoV-2 inactivated vaccine in mice
    Yang, Jie
    Li, Boran
    Yang, Dongsheng
    Wu, Jie
    Yang, Anna
    Wang, Wenhui
    Lin, Fengjie
    Wan, Xin
    Li, YuWei
    Chen, Zhuo
    Lv, Shiyun
    Pang, Deqin
    Liao, Wenbo
    Meng, Shengli
    Lu, Jia
    Guo, Jing
    Wang, Zejun
    Shen, Shuo
    VACCINE, 2023, 41 (41) : 6064 - 6071
  • [3] Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity
    Zheng, Xiaotong
    Yang, Rong
    Zhao, Yuxiu
    Zhang, Yadan
    Yuan, Guangying
    Li, Weidong
    Xiao, Zhuangzhuang
    Dong, Xiaofei
    Ma, Meng
    Guo, Yancen
    Wang, Wei
    Zhao, Xue
    Yang, Hongqiang
    Qiu, Shaoting
    Peng, Zheng
    Liu, Ankang
    Yu, Shouzhi
    Zhang, Yuntao
    VIROLOGY, 2024, 594
  • [4] Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice
    Sundaram, Appavu K.
    Ewing, Daniel
    Liang, Zhaodong
    Jani, Vihasi
    Cheng, Ying
    Sun, Peifang
    Raviprakash, Kanakatte
    Wu, Shuenn-Jue
    Petrovsky, Nikolai
    Defang, Gabriel
    Williams, Maya
    Porter, Kevin R.
    PATHOGENS, 2021, 10 (05):
  • [5] Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
    Wu, Yufei
    Huang, Ping
    Xu, Mingjie
    Zhao, Qianqian
    Xu, Yihui
    Han, Shuyi
    Li, Huanjie
    Wang, Yunshan
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [6] Effect of Inactivated Vaccines Against SARS-CoV-2 on Immunogenicity Outcome
    Ma, Yuke
    Du, Yukuan
    Yang, Jingnan
    Wang, Huichao
    Lin, Xuhong
    DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS, 2025, 19
  • [7] Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
    Li, Tong
    Song, Rui
    Wang, Jingjie
    Zhang, Jianbo
    Cai, Hongxing
    He, Hongmei
    Hu, Wei
    Yu, Dajun
    Wang, Chuanhu
    Pan, Qingbo
    Peng, Mingli
    Ren, Hong
    Zhu, Peng
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 874 - 884
  • [8] Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
    Ao, Ling
    Lu, Ting
    Cao, Yu
    Chen, Zhiwei
    Wang, Yuting
    Li, Zisheng
    Ren, Xingqian
    Xu, Pan
    Peng, Mingli
    Chen, Min
    Zhang, Gaoli
    Xiang, Dejuan
    Cai, Dachuan
    Hu, Peng
    Shi, Xiaofeng
    Zhang, Dazhi
    Ren, Hong
    EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 1126 - 1134
  • [9] Immunogenicity Evaluation of a SARS-CoV-2 BA.2 Subunit Vaccine Formulated with CpG 1826 plus alum Dual Adjuvant
    Yan, Yuhan
    Su, Qiudong
    Yi, Yao
    Shen, Liping
    Bi, Shengli
    BIOMEDICAL AND ENVIRONMENTAL SCIENCES, 2024, 37 (12) : 1409 - 1420
  • [10] Immunogenicity Evaluation of a SARS-CoV-2 BA.2 Subunit Vaccine Formulated with CpG 1826 plus alum Dual Adjuvant
    Yuhan Yan
    Qiudong Su
    Yao Yi
    Liping Shen
    Shengli Bi
    Biomedical and Environmental Sciences, 2024, 37 (12) : 1409 - 1420